Korean J Gynecol Oncol.  2007 Dec;18(4):326-332.

Differential antitumor effects of sequence-dependent model in tumor cell line: association with peroxiredoxin

• Cho HY
• Lee G
• Kang J
• Hah YS
• Jang JS

Abstract

OBJECTIVE
The efficacy of two-drug combination treatment may be schedule-dependent. We investigated a simulated in-vitro interaction between taxol and doxorubicin in a Cervical cancer cell line HeLa and the role of peroxiredoxin in cytotoxicity.
METHODS
Two contradicting schedules of two drugs (taxol followed by doxorubicin or vice versa) were compared each other in terms of cytotoxicity in parental HeLa cell line and the peroxiredoxin (prx)-overexpressing variant. Cytotoxic activity was determined by MTT assay. Cell cycle pertubation was evaluated by flow cytometric analysis. Protein levels were determined by western blot.
RESULTS
The sequential treatment of taxol followed by doxorubicin (T--CONCLUSION
The cytotoxicity of taxol and doxorubicin combination is sequence-dependent in prx-overexpressing cells. These findings suggest that, in prx-overexpressing situation, it is worthy to concern about the treatment sequence when taxol and doxorubicin are supposed to employ to treat cancer of the uterine cervix.

Keyword

Cervix cancer; Sequence-dependent; Taxol; Doxorubicin; Peroxiredoxin

MeSH Terms

Appointments and Schedules
Blotting, Western
Cell Cycle
Cell Line
Cell Line, Tumor*
Cyclin D1
Doxorubicin
HeLa Cells
Humans
Paclitaxel
Parents
Peroxiredoxins*
Uterine Cervical Neoplasms
Cyclin D1
Doxorubicin
Paclitaxel
Peroxiredoxins